Nanoparticulate drug delivery systems

Clearly, the definitive characteristic of any nanoparticulate drug delivery system will be its submicrometer diameter. Sizing such particles in the suboptical region can be difficult as the measuring technique itself may alter size and properties by either hydrating or aggregating the particles. This will have a profound influence on the size of the particle [59]. Haskell [134] has discussed the various optical techniques available to measure the size of nanoparticles. 

Fig. 3.20 Nanoparticulate drug delivery systems formed by amphiphilic block copolymers and their general characteristics. (From ref. [112])...

Block Copolymers are macromolecules which are composed of blocks usually in linear as it shown in Fig. 3.20, where it is illustrated a classical block copolymer. Main block copolymers are amphiphilic block copolymers having united hydrophilic blocks to hydrophobic blocks. Amphiphilic block copolymer have surfactant properties and form different kinds of associations, such as micelles, nanospheres, nanocapsules and polymersomes This tipe of association can act like excellent vehicles of several active principles. The composition, aggregate formation and the different applications of these materials have been reviewed [112], Figure 3.20 also illustrates the nanoparticulate drug delivery systems formed by amphiphilic block copolymers and their general characteristics. 

Nanoparticulate Drug Delivery Systems, edited by Deepak Thassu, Michel Deleers, and Yashwant Pathak... 

Micro- and nanoparticulate drug delivery systems as well as delivery systems based on liposomes are described in detail in Chapters 9 and 10. Besides other advantages which are discussed in the mentioned chapters, these formulations are capable of protecting incorporated drugs from enzymatic degradation. 

Bernkop-Schniirch, A., Weithaler, A., Albrecht, K., and Greimel, A. Thiomers preparation and in vitro evaluation of a mucoadhesive nanoparticulate drug delivery system. Int. J. Pharm. 2006 317, 1,76-81. 

Table 10. Some examples of hydrophilic nanoparticulate drug delivery systems ...

Parallel to the increasing interest and successful licensing and commercialization of nanoparticulate pharmaceutical products, CDs have also been incorporated into nanoparticulate drug delivery systems for several purposes. This can be... 

In light of current research, this chapter will deal with the following issues concerning the use of CDs and derivatives as nanomaterials for drug delivery use of CDs (natural and synthetic) derivatives in the pharmaceutical field and application of CDs in nanoparticulate drug delivery systems. A major part of the chapter will be focused on new CD derivatives, amphiphilic CDs, and the characterization, efficacy, and safety of nanoparticles prepared from amphiphilic CDs. 

Thassu D, Deleers M, Pathak Y, eds. Nanoparticulate Drug Delivery Systems. New York Informa Healthcare, 2007. 

Rao, G. C., et al.. Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems. Pharmazie 2004, 59, 5-9. 

For the more important copolymer PLGA, apart from the intrinsic possibility to tune such factors as degree of crystallinity and hydrophilicity (and thus to influence, above all, the degradation behavior) simply by adjusting the lactide to glycolide ratio, similar approaches exist. PLGA is in most cases functionalized after polymerization and is often used as a material for microparticulate [55] and nanoparticulate drug-delivery systems [56]. 

Figure 7.1 Representative nanoparticulate drug delivery systems for treating bone diseases.

It was suggested that chitosan based tablets are safe for human use (22). Chitosan-based micro- or nanoparticulate drug delivery systems have been reviewed (23). 

D. Thassu, M. Deleers and Y. Pathak, Eds., Nanoparticulate Drug Delivery Systems, Informa Healthcare USA, New York, NY (2007). 

Fazil, M., Hassan, M.Q., Baboota, S., Ah, J., 2015. Biodegradable intranasal nanoparticulate drug delivery system of risedronate sodium for osteoporosis. Drug Deliv. 25, 1—11. 

C. M. Keck, and R.H. Muller, Nanotoxicological classification system (NCS) - A guide for the risk benefit assessment of nanoparticulate drug delivery systems, European Journal of Pharmaceutics and Biopharmaceutics, 84 (3), 445-448, 2013. 

---